Table 3 Secondary efficacy evaluation
Treatment group | P value | ||
|---|---|---|---|
GXST (n = 143) | Placebo (n = 144) | ||
Nitroglycerin consumption | |||
Highly effective | 57 (39.9%) | 12 (8.3%) | < 0.0001 |
Effective | 59 (41.3%) | 60 (41.7%) | 0.52 |
No efficacy | 27 (18.8%) | 72 (50.0%) | < 0.0001 |
SAQ score | 65.6 ± 10.6 | 56.3 ± 13.4 | < 0.001 |
Physical limitations | 60.1 ± 10.5 | 58.0 ± 11.7 | 0.11 |
Angina stability | 79.6 ± 19.4 | 66.0 ± 22.6 | < 0.001 |
Angina frequency | 59.7 ± 20.1 | 49.5 ± 20.0 | < 0.001 |
Treatment satisfaction | 65.6 ± 14.3 | 54.5 ± 19.0 | < 0.001 |
QOL | 62.9 ± 16.1 | 53.4 ± 19.1 | < 0.001 |
ETT | |||
Time to onset of chest pain (s) | 517.6 ± 165.2 | 493.2 ± 152.9 | 0.81 |
Time to 1 mm ST-depression (s) | 219.7 ± 172.2 | 257.7 ± 183.6 | 0.37 |